ASCO GU 2019: First-line pembrolizumab shows promise in non-clear cell RCC
The results from the following study were presented at the [...]
Pembrolizumab plus axitinib combination promising as a first-line treatment for advanced RCC
Results from the KEYNOTE-426 phase 3 study show that the [...]
Epacadostat plus pembrolizumab combination shows promise in advanced solid tumours
Headline results from the open-label phase I/II ECHO-202/KEYNOTE-037 trial assessing [...]
Managing immune-related adverse events
Immune-related adverse events (irAEs) are side effects that can develop [...]
Latest clinical trial results for the treatment of kidney cancer
These short videos explain the latest results from the following [...]
Pembrolizumab shows promise as first-line treatment for advanced kidney cancer
The immune checkpoint (PD-1) inhibitor, pembrolizumab, shows promise as a [...]
Lenvatinib plus pembrolizumab shows promise for metastatic kidney cancer
The results from the renal cell carcinoma (RCC) group of [...]
Promising new immunotherapy drug for advanced/metastatic kidney cancer
Immunotherapy has revolutionised the treatment of renal cell carcinoma (RCC). [...]
Combination therapies for kidney cancer
The following is a Practice Update interview with Dr Hans Hammers, Associate [...]
Axitinib plus pembrolizumab combination shows promise for advanced kidney cancer
Data from a recent phase 1b study has shown that [...]
